Excerpts

OS was significantly associated with younger age ( p = 0.030) and showed a trend for PIK3CA mutations ( p = 0.061).

Adding the loss of expression of CDX2 to the multivariate model showed it to have a tendency toward significance as increased risk of death (HR = 2.74, 95% CI (0.96–7.84), p = 0.061), and it was statistically significant for risk of death or relapse (HR = 2.77, 95% CI (1.06–7.23), p = 0.037). 3.2.

miR-210 showed a trend toward decrease (Z = −1.870, p = 0.061), while miR-let-7b was slightly reduced (Z = −1.964, p = 0.049).

Results of logistic regression showed a trend toward decreased local control probability with every single unitary increase in PTV_SIP absolute volume (OR 1.024, CI 0.99–1.05, p = 0.061), where 1.024 is the estimated local control odds ratio associated with a 1 cc increase in PTV_SIP absolute volume.

However, we did not detect any differences when comparing genotypic frequencies, although a trend toward significance was observed ( p = 0.0615).

Statistically significant adverse effects on body weight were demonstrated for cisplatin treatment compared to the vehicle from Day 4 post-treatment to Day 13 (d4: p = 0.0006; d5: p = 0.0009; d8: p = 0.0012: d9: p < 0.0001; d10: p = 0.0002; d11–d13: p < 0.0001), except on Days 6 and 7 with results very close to significance ( p = 0.0619 and p = 0.0774, respectively) ( Supplementary Table S1 ).

The study was negative in the primary efficacy analysis, with a median follow-up of 15.0 months; however, the combination arm showed a trend for longer survival compared to standard treatment (HR = 0.71; 95% CI, 0.50–1.02; p = 0.062).

In the case of HPV-positive OPC, no tumor dimensional variables were risk factors for ECS, while the largest node size of LNM was selected for a multivariable model with a marginal significance ( p = 0.062).

In particular, the DM rate was higher, marginally significant, in the high-risk sub-set of patients reaching a 24.5% compared to 16.2% of low and intermediate risk ( p = 0.062).

While the SLFN11 H-score assessed in cancer cells showed only a borderline significant association (HR = 0.62, 95% confident interval (CI) = 0.38–1.02, p = 0.0620), overall and non-cancer higher SLFN11 H-scores were strongly associated with longer progression-free interval (PFI) by univariable analysis (HR = 0.50, 95% CI = 0.33–0.75, p = 0.0009; and HR = 0.54, 95% CI = 0.36–0.81, p = 0.0028, respectively).

In the first IC cycle, the rates were 14.5% versus 22.0% ( p = 0.045), and in the first CCRT cycle, a favorable trend was observed (18.2% vs. 25.7%, p = 0.062).

PFS showed a trend toward worse outcomes with an increased metastatic burden (log-rank p = 0.062; Figure 3 D).

Baseline ctDNA positivity was strongly associated with poorer outcomes: patients with detectable ctDNA at M0 had significantly reduced recurrence-free survival (2-year RFS: 18% vs 60%, log-rank p = 0.010) and showed a trend toward inferior overall survival (2-year OS: 40% vs 78%, log-rank p = 0.062).

Receiving ICI beyond the first line showed a trend toward worse PFS (adjusted HR: 1.85; p = 0.062) but did not reach statistical significance.

The comparison between 6 months and baseline approached significance ( p = 0.062), while the difference between 6 months and 12 months was not statistically significant ( p = 0.8).

12.9 months; p = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response ( p = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend ( p = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement.

This was further emphasized when we analyzed the subgroup of masses, in which the multiparametric radiomics model with individual BI-RADS descriptors and ADC values provided borderline significance when compared with the accuracy of radiologists based on multiparametric MRI using ADC values (91.7% vs. 86.9%; p = 0.063).

However, there was a positive trend towards a reduction in index lesion recurrences in the patients who received multimodality therapy ( p = 0.063).

In our cohort, MHC I and MHC II expression showed an increasing trend in cSCC tissues with high COPB2 expression (31.8% and 45.5%, respectively) than in those with low COPB2 expression (13.7% and 23.3%, respectively) ( p = 0.063 and P = 0.059, respectively) ( Table 2 ).

Kaplan–Meier analysis confirmed that greater reductions in SMA significantly increased the risk of mortality (HR 5.1, 95% CI: 1.05–24.79; p = 0.025) and showed a trend toward higher risk of disease progression (HR 2.58, 95% CI: 0.89–7.49; p = 0.063).

PD-L1 expression ≥ 1% showed a trend toward improved OS (HR 3.72, p = 0.063).

Social support showed a trend toward significance for depression levels ( p = 0.063), suggesting a potential association that did not meet the statistical threshold.

Protocol B showed an interesting trend toward improved outcomes for patients with RT-PCR positive SLN who underwent completion dissection ( p = 0.063).

Furthermore, the frequency of ASS1 loss or low ASS1 expression was higher in patients following neoadjuvant therapy ( p = 0.063; barely not statistically significant).

However, those who were in the highest tertile of the network-specific score showed a marginally significant decreasing association with GC risk (OR = 0.56, 95% CI = 0.32–1.00), and there was a borderline significant linear trend ( p = 0.064) in model II.